
The FDA has approved pembrolizumab monotherapy as a treatment for patients with recurrent, locally advanced, or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1, as determined by an FDA-approved test, and who have disease progression after ≥1 prior systemic regimen.








